vs
Side-by-side financial comparison of Autolus Therapeutics plc (AUTL) and NexPoint Real Estate Finance, Inc. (NREF). Click either name above to swap in a different company.
Autolus Therapeutics plc is the larger business by last-quarter revenue ($21.2M vs $11.1M, roughly 1.9× NexPoint Real Estate Finance, Inc.). NexPoint Real Estate Finance, Inc. runs the higher net margin — 216.6% vs -373.3%, a 589.9% gap on every dollar of revenue.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of next-generation engineered chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. It operates in the global oncology biotech market, advancing a pipeline of targeted immunotherapy candidates across multiple clinical development stages.
NexPoint Real Estate Finance, Inc. is a US-based commercial real estate finance firm that offers structured financing solutions for multifamily, office, industrial, and hospitality properties. It focuses on originating, managing and servicing a diversified portfolio of mortgage loans and real estate-related investments to deliver stable risk-adjusted returns to stakeholders.
AUTL vs NREF — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.2M | $11.1M |
| Net Profit | $-79.1M | $24.0M |
| Gross Margin | — | — |
| Operating Margin | -337.9% | — |
| Net Margin | -373.3% | 216.6% |
| Revenue YoY | — | -48.8% |
| Net Profit YoY | 3.6% | 58.7% |
| EPS (diluted) | $-0.30 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $11.1M | ||
| Q3 25 | $21.2M | $12.5M | ||
| Q2 25 | $20.9M | $12.1M | ||
| Q1 25 | $9.0M | $11.5M | ||
| Q4 24 | — | $21.7M | ||
| Q3 24 | $0 | $12.5M | ||
| Q2 24 | $0 | $6.7M | ||
| Q1 24 | $10.1M | $-12.8M |
| Q4 25 | — | $24.0M | ||
| Q3 25 | $-79.1M | $50.9M | ||
| Q2 25 | $-47.9M | $22.3M | ||
| Q1 25 | $-70.2M | $26.0M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | $-82.1M | $23.3M | ||
| Q2 24 | $-58.3M | $12.1M | ||
| Q1 24 | $-52.7M | $-14.6M |
| Q4 25 | — | — | ||
| Q3 25 | -337.9% | — | ||
| Q2 25 | -292.6% | — | ||
| Q1 25 | -726.3% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -384.1% | — |
| Q4 25 | — | 216.6% | ||
| Q3 25 | -373.3% | 407.0% | ||
| Q2 25 | -229.0% | 184.5% | ||
| Q1 25 | -781.1% | 225.6% | ||
| Q4 24 | — | 69.9% | ||
| Q3 24 | — | 186.4% | ||
| Q2 24 | — | 179.7% | ||
| Q1 24 | -522.1% | 114.3% |
| Q4 25 | — | $0.47 | ||
| Q3 25 | $-0.30 | $1.14 | ||
| Q2 25 | $-0.18 | $0.54 | ||
| Q1 25 | $-0.26 | $0.70 | ||
| Q4 24 | — | $0.71 | ||
| Q3 24 | $-0.31 | $0.74 | ||
| Q2 24 | $-0.22 | $0.40 | ||
| Q1 24 | $-0.24 | $-0.83 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.1M | $31.1M |
| Total DebtLower is stronger | — | $771.2M |
| Stockholders' EquityBook value | $265.5M | $388.0M |
| Total Assets | $661.9M | $5.3B |
| Debt / EquityLower = less leverage | — | 1.99× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $31.1M | ||
| Q3 25 | $86.1M | $17.9M | ||
| Q2 25 | $123.8M | $9.1M | ||
| Q1 25 | $95.8M | $19.2M | ||
| Q4 24 | — | $3.9M | ||
| Q3 24 | $657.1M | $34.7M | ||
| Q2 24 | $705.9M | $4.3M | ||
| Q1 24 | $758.5M | $13.5M |
| Q4 25 | — | $771.2M | ||
| Q3 25 | — | $720.9M | ||
| Q2 25 | — | $815.6M | ||
| Q1 25 | — | $831.5M | ||
| Q4 24 | — | $799.3M | ||
| Q3 24 | — | $815.5M | ||
| Q2 24 | — | $861.0M | ||
| Q1 24 | — | $843.3M |
| Q4 25 | — | $388.0M | ||
| Q3 25 | $265.5M | $375.4M | ||
| Q2 25 | $346.5M | $348.2M | ||
| Q1 25 | $371.1M | $343.7M | ||
| Q4 24 | — | $336.5M | ||
| Q3 24 | $477.0M | $335.8M | ||
| Q2 24 | $527.8M | $327.5M | ||
| Q1 24 | $582.0M | $327.1M |
| Q4 25 | — | $5.3B | ||
| Q3 25 | $661.9M | $5.3B | ||
| Q2 25 | $721.0M | $5.4B | ||
| Q1 25 | $746.3M | $5.4B | ||
| Q4 24 | — | $5.4B | ||
| Q3 24 | $827.5M | $5.7B | ||
| Q2 24 | $853.6M | $6.6B | ||
| Q1 24 | $901.4M | $7.1B |
| Q4 25 | — | 1.99× | ||
| Q3 25 | — | 1.92× | ||
| Q2 25 | — | 2.34× | ||
| Q1 25 | — | 2.42× | ||
| Q4 24 | — | 2.38× | ||
| Q3 24 | — | 2.43× | ||
| Q2 24 | — | 2.63× | ||
| Q1 24 | — | 2.58× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.9M | $-4.5M |
| Free Cash FlowOCF − Capex | $-72.3M | — |
| FCF MarginFCF / Revenue | -341.2% | — |
| Capex IntensityCapex / Revenue | 20.8% | — |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $-322.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-4.5M | ||
| Q3 25 | $-67.9M | $8.1M | ||
| Q2 25 | $-72.8M | $3.3M | ||
| Q1 25 | $-75.6M | $16.0M | ||
| Q4 24 | — | $4.4M | ||
| Q3 24 | $-76.7M | $14.7M | ||
| Q2 24 | $-51.1M | $-7.5M | ||
| Q1 24 | $-40.5M | $17.7M |
| Q4 25 | — | — | ||
| Q3 25 | $-72.3M | — | ||
| Q2 25 | $-80.1M | — | ||
| Q1 25 | $-83.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-86.3M | — | ||
| Q2 24 | $-51.9M | — | ||
| Q1 24 | $-41.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | -341.2% | — | ||
| Q2 25 | -382.6% | — | ||
| Q1 25 | -933.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -406.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 20.8% | — | ||
| Q2 25 | 34.8% | — | ||
| Q1 25 | 91.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 5.3% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.62× | ||
| Q4 24 | — | 0.29× | ||
| Q3 24 | — | 0.63× | ||
| Q2 24 | — | -0.62× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
